The CRISPR sector faced contrasting developments: Intellia reported a fatality and an FDA clinical‑hold risk in its MAGNITUDE Phase III program after a patient developed severe liver injury, prompting scrutiny of in‑vivo CRISPR delivery safety. At the same time, other groups published promising clinical and preclinical CRISPR advances, underscoring both the promise and the immediate safety questions for in‑body editing. Parallel technical work is pushing vector and payload innovations—efforts to shrink CRISPR cargo and improve rAAV vector capacity were highlighted as key enablers for safer, more effective in‑vivo editing. Regulators and sponsors are expected to tighten monitoring and risk‑mitigation strategies as the technology advances.